Lineage Cell Therapeutics acquires NeuroAirmid Therapeutics, adding Huntington's disease program

• Lineage Cell Therapeutics acquired NeuroAirmid Therapeutics, gaining certain worldwide rights to HUNT1, a clinical-stage stem cell therapy for Huntington’s disease.
• Investors received approximately $4.7 million at closing, split roughly equally between cash and Lineage common stock.
• Additional payments include up to $5 million on closing’s first anniversary and up to $48 million in development, regulatory and clinical milestones.
• HUNT1 adds a third clinical-stage asset; six patients have received treatment in the ongoing Phase 1b/2a REGEN4HD trial.
• The buyer assumes estimated clinical development costs of $3.1 million through February 2030, alongside future manufacturing and post-study development responsibilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611121603BIZWIRE_USPR_____20261112_BW922275) on November 12, 2026, and is solely responsible for the information contained therein.